secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0000950170-22-026760
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab
--------------------------------------------------------------------------------

- Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).
- Confirmed ORR: doublet 41%, triplet 40% vs. monotherapy 27% in PD-L1≥50% 1L NSCLC.
- Six-month PFS rate: doublet 65%, triplet 63% vs. monotherapy 43%; median follow-up ~12 mo.
- No new safety signals; Grade≥3 AEs: doublet 47%, triplet 52% vs. monotherapy 58%.
- Trial continues to monitor overall survival; data cutoff Aug 31, 2022 (n=149 safety, 133 efficacy).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/0000950170-22-026760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/rcus-20221219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer